Precigen, Inc. announced that the FDA has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). Papzimeosis the first and only FDA-approved therapy… read more.
Iovance Biotherapeutics Inc. announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Amtagvi (lifileucel), a tumor-derived autologous T cell immunotherapy. Amtagvi is indicated for… read more.
The FDA has updated Skysona’s indication, allowing it to be used only in patients who do not have an available human leukocyte antigen (HLA)-matched donor for stem cell… read more.
Novo Nordisk announced that the FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic… read more.
NICE (UK): Ruxolitinib cream is not recommended, within its marketing authorisation, for treating non-segmental vitiligo with facial involvement in people 12 years and over. This recommendation is not intended… read more.
Basilea Pharmaceutica announced that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil (Exblifep), a clinical phase… read more.
ImmunityBio Inc. announced the Michael E. DeBakey Department of Veterans Affairs (VA) Medical Center in Houston recently became the first VA hos Anktiva (nogapendekin alfa inbakicept-pmln)ital in the… read more.
Catalyst Pharmaceuticals, Inc. announced the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Small Cell Lung Cancer (SCLC) now include new additions involving Lambert Eaton… read more.
Insmed announced positive topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase III study to assess the efficacy, safety, and tolerability of brensocatib in patients… read more.
Boehringer Ingelheim’s Hernexeos (zongertinib tablets) has been approved by the FDA. The kinase inhibitor is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small… read more.
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF), already licensed for the treatment of chronic obstructive pulmonary disease (COPD) in adults, has now been approved for use in the… read more.
Astellas announced the submission of a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Conditional Approval of avacincaptad pegol intravitreal solution (ACP),… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
